GLP-1 weight loss medications have evolved from ~15% weight loss with semaglutide (Wegovy 2.4 mg) to ~20%+ with higher-dose semaglutide (7.2 mg) and dual agonists like tirzepatide (Zepbound). Tirzepatide still shows slightly higher peak results, but high-dose Wegovy significantly narrows the gap, giving clinicians two viable paths to achieve near–bariatric-level weight loss. The Big Shift:
After 30 years helping thousands of patients lose weight, here’s what we’re telling our patients at BeLite Medical Center about the new oral GLP-1 options—and what the headlines are getting wrong. The phone at our Fairfax clinic hasn’t stopped ringing since December 22nd, when the FDA approved the first oral GLP-1 for weight loss. Patients
In May 2025, the New England Journal of Medicine published the first head-to-head clinical trial comparing two of the most effective anti-obesity medications on the market: tirzepatide (Zepbound) and semaglutide (Wegovy). This was the phase 3b open label extension of the SURMOUNT-5 clinical trial involving 751 non-diabetic obese patients. The main finding was that tirzepatide led to significantly more weight loss than semaglutide over 72
In the ever evolving field of weight management, two recently marketed drugs have captured significant attention: Wegovy (semaglutide) and Zepbound (tirzepatide). While originally designed to address type 2 diabetes, both medications demonstrated impressive results in overweight individuals who do not have type 2 diabetes. This post will explore what current clinical trial data tells us
If you’ve been prescribed Zepbound (tirzepatide) or Wegovy (semaglutide) for weight management, you’re already on a promising path toward achieving your health goals. These medications work by reducing appetite and craving, reducing “food noise,” slowing digestion, making it easier to eat less and lose weight. Most patients just don’t feel like eating as much as
